CD3-Binding Proteins with CDR-Tuned Affinity Diversity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-CD3ε antibodies, such as SP-34, lack diversity in binding affinities, stability, and manufacturability, necessitating the development of new molecules with tailored CD3ε binding properties for improved therapeutic efficacy and safety.
Innovation Solution
Development of target-binding proteins with specific heavy and light chain variable domains that exhibit enhanced binding affinities and stability, including humanized sequences and multispecific capabilities, such as scFv antibodies, to address the limitations of existing anti-CD3ε antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-CD3ε antibodies (e.g., SP-34) are used, then binding specificity to CD3ε is achieved, but binding affinity diversity and therapeutic efficacy are limited
Solution Approach 1:
The patent applies parameter changes by systematically mutating amino acid residues at specific positions in the complementarity determining regions (CDRs) of the antibody variable domains. This generates a library of anti-CD3ε binding proteins with varying binding affinities, allowing selection of molecules optimized for specific therapeutic applications. The parameter changes are made in the CDR sequences to create diversity in binding characteristics while maintaining CD3ε specificity.
2Reliability
If additional anti-CD3ε binding proteins with tailored binding affinities are developed, then therapeutic efficacy for specific diseases is improved, but development complexity and manufacturing challenges increase
Solution Approach 1:
The patent segments the antibody molecule into distinct functional regions: complementarity determining regions (CDRs) that interact with CD3ε and framework regions that provide structural stability. By focusing mutations on specific CDR segments while maintaining stable frameworks, the patent creates manageable diversity in binding properties. This segmentation allows systematic exploration of binding affinity variations without compromising overall molecular stability.
Solution Approach 2:
The patent applies local quality by making targeted mutations only in specific regions (CDRs) while maintaining the overall structure and stability of the antibody molecule. Different CDR positions are mutated to achieve specific binding characteristics needed for different diseases, while the rest of the molecule maintains conserved structural features for stability and manufacturability.
3Reliability
If full-length anti-CD3ε antibodies are used, then binding specificity is achieved, but manufacturability and stability in alternative molecular structures are reduced
Solution Approach 1:
The patent extracts and focuses on the variable domains (VH and VL) containing the CDRs that are critical for CD3ε binding, while separating these from the constant regions. This extraction enables the creation of simplified binding proteins that maintain specificity through the variable domains while improving manufacturability by reducing the overall molecular size and complexity compared to full-length antibodies.
Data Source
AI summary
The present disclosure includes target-binding proteins having heavy chain variable domains and light chain variable domains with specific sequences that bind to CD3 epsilon and wherein the heavy chain variable domains and the light chain variable domains are disposed within one or more polypeptides. The present disclosure also includes compositions, nucleic acids, vectors, cells, and methods of making and using the proteins, compositions, and nucleic acids.